Literature DB >> 11810606

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

Clyde Thornsberry1, Daniel F Sahm, Laurie J Kelly, Ian A Critchley, Mark E Jones, Alan T Evangelista, James A Karlowsky.   

Abstract

The ongoing TRUST (Tracking Resistance in the United States Today) study, which began monitoring antimicrobial resistance among respiratory pathogens in 1996, routinely tracks resistance at national and regional levels. The 1999-2000 TRUST study analyzed 9499 Streptococcus pneumoniae, 1934 Haemophilus influenzae, and 1108 Moraxella catarrhalis isolates that were prospectively collected from 239 laboratories across the 9 US Bureau of the Census regions. Penicillin-resistant S. pneumoniae varied significantly by region, from 8.3% to 24.8% (P<.001). In each region, penicillin resistance closely predicted resistance to other beta-lactams, macrolides, and trimethoprim-sulfamethoxazole. Levofloxacin resistance was 0.5% nationally (regional range, 0.1%-1.0%). Multidrug resistance also varied significantly (P<.001) by region. beta-Lactamase production among H. influenzae varied significantly (regional range, 24.0%-34.6%) and M. catarrhalis (86.2%-96.8%) also varied by region. Notable variation in regional antimicrobial resistance rates (S. pneumoniae) and beta-lactamase production (H. influenzae, M. catarrhalis) exists throughout the United States.

Entities:  

Mesh:

Year:  2002        PMID: 11810606     DOI: 10.1086/324525

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  38 in total

1.  Gram-negative Diplococcal Respiratory Infections.

Authors:  Nargis Naheed; Maqsood Alam; Larry I. Lutwick
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

2.  In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Authors:  Laurel S Almer; Jennifer B Hoffrage; Erika L Keller; Robert K Flamm; Virginia D Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

3.  Trends in drug resistance, serotypes, and molecular types of Streptococcus pneumoniae colonizing preschool-age children attending day care centers in Lisbon, Portugal: a summary of 4 years of annual surveillance.

Authors:  S Nunes; R Sá-Leão; J Carriço; C R Alves; R Mato; A Brito Avô; J Saldanha; J S Almeida; I Santos Sanches; H de Lencastre
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

4.  Antimicrobial resistance of Streptococcus pneumoniae isolates in Athens, Greece.

Authors:  S Kanavaki; E Mantadakis; S Karabela; M Anatoliotaki; M Makarona; H Moraitou; A Pefanis; G Samonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

5.  In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides.

Authors:  Darren Abbanat; Glenda Webb; Barbara Foleno; Y Li; Mark Macielag; Deborah Montenegro; Ellyn Wira; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables.

Authors:  Jeffrey P Hammel; Sujata M Bhavnani; Ronald N Jones; Alan Forrest; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

7.  Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  Tatiana Bogdanovich; Catherine Clark; Lois Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 8.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 9.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Maintaining fluoroquinolone class efficacy: review of influencing factors.

Authors:  W Michael Scheld
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.